SIFI, a leading pharmaceutical company in the development of innovative solutions for the treatment of eye diseases, is pleased to announce the launch of EpiColin, comprehensive support for glaucoma patients. After Amiriox and Ecbirio, hypotonizing drugs fully reimbursed by the NHS, EpiColin is the third innovation in the glaucoma therapeutic area introduced by SIFI in the second half of 2022.
EpiColin is a dietary supplement based on plant extracts of Coleus forskohlii and green tea, with citicoline, homotaurine, group B vitamins and vitamin E, a valuable supplement to hypotonizing therapy for the management of glaucoma, a chronic degenerative disease.
“It is now known that eye pressure is not the only risk factor for glaucoma progression.” stated the Dr. Matteo Sacchi, Head of the Glaucoma Center of the University Eye Clinic, San Giuseppe Hospital -IRCCS MultiMedica, Milan, alongside a recent national congress dedicated to glaucoma, "Growing attention is now also placed on aspects such as oxidative stress, neuroinflammation and mitochondrial dysfunction, confirming the importance of a new synergistic therapeutic approach that includes a short- and long-term perspective view of the patient."
In patients with glaucoma, the disease can in fact progress despite the reduction of intra-ocular pressure1-3, and it is therefore necessary to support the therapy to prevent or delay this retinal cell degenerative process4,5. The complete EpiColin therapeutic supplementation has been designed to produce a significant neuroprotective and antioxidant effect thanks to the synergistic action of the individual components, known and reliable, in support of the hypotonizing therapy. The neuroprotective effect of nutraceuticals has been demonstrated both in preclinical in vitro and in vivo studies, and in clinical studies6.
According to recent estimates in Italy there are about 550.000 confirmed patients suffering from glaucoma with an incidence that increases with age, affecting more than 10% of subjects over 70 years of age. It is estimated that in the next 20 years there will be a 33% increase in confirmed cases in Italy with peaks of 50% in the regions where more significant aging is expected7.
Glaucoma is an eye disease generally related to too high pressure in the eye. According to the WHO, around 60 million people are affected worldwide8. It is the second cause of blindness globally after cataracts, but it is the first irreversible9.
AMIRIOX™ and ECBIRIO™ Amiriox™ (bimatoprost 0,3 mg/ml) and Ecbirio™ (bimatoprost 0,3 mg/ml + timolol 5 mg/ml) are, respectively, the new monotherapy and fixed combination eye drops approved for the reduction of elevated intraocular pressure in chronic open-angle disease patients with glaucoma and ocular hypertension. Amiriox™ and Ecbirio™ are available in a multidose preservative-free formulation that preserves the ocular surface, valid for up to three months after opening.
BlogInnovazione.it
Millions of people pay for streaming services, paying monthly subscription fees. It is common opinion that you…
Coveware by Veeam will continue to provide cyber extortion incident response services. Coveware will offer forensics and remediation capabilities…
Predictive maintenance is revolutionizing the oil & gas sector, with an innovative and proactive approach to plant management.…
The UK CMA has issued a warning about Big Tech's behavior in the artificial intelligence market. There…
